These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 17184594)
1. Design, synthesis, antitumor evaluations and molecular modeling studies of novel 3,5-substituted indolin-2-one derivatives. Li HH; Zheng XH; Tan JZ; Chen LL; Liu H; Luo XM; Shen X; Lin LP; Chen KX; Ding J; Jiang HL Acta Pharmacol Sin; 2007 Jan; 28(1):140-52. PubMed ID: 17184594 [TBL] [Abstract][Full Text] [Related]
2. [Synthesis of 1-furfuryl-indolin-2-one derivatives and preliminary evaluation of their antitumor activities]. Dong XC; Zhou FS; Zheng JB; Wen R Yao Xue Xue Bao; 2008 Jan; 43(1):54-9. PubMed ID: 18357732 [TBL] [Abstract][Full Text] [Related]
3. Discovering novel 3-nitroquinolines as a new class of anticancer agents. Li HH; Huang H; Zhang XH; Luo XM; Lin LP; Jiang HL; Ding J; Chen KX; Liu H Acta Pharmacol Sin; 2008 Dec; 29(12):1529-38. PubMed ID: 19026174 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors. Jin Y; Li HY; Lin LP; Tan J; Ding J; Luo X; Long YQ Bioorg Med Chem; 2005 Oct; 13(19):5613-22. PubMed ID: 15993078 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and antitumor evaluation of a new series of N-substituted-thiourea derivatives. Li J; Tan JZ; Chen LL; Zhang J; Shen X; Mei CL; Fu LL; Lin LP; Ding J; Xiong B; Xiong XS; Liu H; Luo XM; Jiang HL Acta Pharmacol Sin; 2006 Sep; 27(9):1259-71. PubMed ID: 16923349 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. Sun L; Tran N; Tang F; App H; Hirth P; McMahon G; Tang C J Med Chem; 1998 Jul; 41(14):2588-603. PubMed ID: 9651163 [TBL] [Abstract][Full Text] [Related]
7. Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives. Cho TP; Dong SY; Jun F; Hong FJ; Liang YJ; Lu X; Hua PJ; Li LY; Lei Z; Bing H; Ying Z; Qiong LF; Bei FB; Guang LL; Shen GA; Hong SG; Hong SW; Tai MX J Med Chem; 2010 Nov; 53(22):8140-9. PubMed ID: 21028894 [TBL] [Abstract][Full Text] [Related]
8. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation. Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of 2-indolinone derivatives as potential antitumor agents. Zou H; Zhang L; Ouyang J; Giulianotti MA; Yu Y Eur J Med Chem; 2011 Dec; 46(12):5970-7. PubMed ID: 22019188 [TBL] [Abstract][Full Text] [Related]
11. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity. Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863 [TBL] [Abstract][Full Text] [Related]
12. Quinols as novel therapeutic agents. 2.(1) 4-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and related agents as potent and selective antitumor agents. Berry JM; Bradshaw TD; Fichtner I; Ren R; Schwalbe CH; Wells G; Chew EH; Stevens MF; Westwell AD J Med Chem; 2005 Jan; 48(2):639-44. PubMed ID: 15658878 [TBL] [Abstract][Full Text] [Related]
13. DNA-based electrochemical biosensors for monitoring of bis-indoles as potential antitumoral agents, chemistry, X-ray crystallography. Maciejewska D; Szpakowska I; Wolska I; Niemyjska M; Mascini M; Maj-Zurawska M Bioelectrochemistry; 2006 Sep; 69(1):1-9. PubMed ID: 16307909 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and anticancer activity of Indolin-2-one derivatives bearing the 4-thiazolidinone moiety. Wang S; Zhao Y; Zhu W; Liu Y; Guo K; Gong P Arch Pharm (Weinheim); 2012 Jan; 345(1):73-80. PubMed ID: 21932254 [TBL] [Abstract][Full Text] [Related]
15. Synthesis, antiproliferative activity, and structure-activity relationships of 3-aryl-1H-quinolin-4-ones. Xiao ZP; Li HQ; Shi L; Lv PC; Song ZC; Zhu HL ChemMedChem; 2008 Jul; 3(7):1077-82. PubMed ID: 18433075 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of novel 7-azaindazolyl-indolyl-maleimide derivatives as antitumor agents and protein kinase C inhibitors. Ye Q; Cao J; Zhou X; Lv D; He Q; Yang B; Hu Y Bioorg Med Chem; 2009 Jul; 17(13):4763-72. PubMed ID: 19447039 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase. Abouzid K; Shouman S Bioorg Med Chem; 2008 Aug; 16(16):7543-51. PubMed ID: 18678492 [TBL] [Abstract][Full Text] [Related]
18. Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases. Sun L; Tran N; Liang C; Hubbard S; Tang F; Lipson K; Schreck R; Zhou Y; McMahon G; Tang C J Med Chem; 2000 Jul; 43(14):2655-63. PubMed ID: 10893303 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and cytotoxicity of novel 3-amino-4-indolylmaleimide derivatives. Zhao SY; Yang YW; Zhang HQ; Yue Y; Fan M Arch Pharm Res; 2011 Apr; 34(4):519-26. PubMed ID: 21544716 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and antiproliferative activities of indolin-2-one derivatives bearing amino acid moieties. Sassatelli M; Debiton E; Aboab B; Prudhomme M; Moreau P Eur J Med Chem; 2006 Jun; 41(6):709-16. PubMed ID: 16675065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]